Table 2. Patients receiving HEC and MEC chemotherapy for different cancer indications.
HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy
| Indication | Total frequency | Chemotherapy received | Frequency n (%) |
| Breast Cancer | 223 | Doxorubicin and Cyclophosphamide | 201 (90.13%) |
| Epirubicin and Cyclophosphamide | 6 (2.69%) | ||
| Cisplatin | 2 (0.90%) | ||
| Cisplatin and Docetaxel | 2 (0.90%) | ||
| Docetaxel | 1 (0.45%) | ||
| Docetaxel and Cyclophosphamide | 3 (1.35%) | ||
| Docetaxel, Carboplatin, Pertuzumab, Trastuzumab, and Hyaluronidase | 2 (0.90%) | ||
| Gemcitabine and Carboplatin | 1 (0.45%) | ||
| Paclitaxel | 1 (0.45%) | ||
| Paclitaxel and Carboplatin | 1 (0.45%) | ||
| Paclitaxel, Carboplatin, and Pembrolizumab | 2 (0.90%) | ||
| Trastuzumab Emtansine | 1 (0.45%) | ||
| Stomach cancer | 47 | FLOT regimen (Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel) | 41 (87.23%) |
| Docetaxel, Oxaliplatin, and tab Capecitabine | 3 (6.38%) | ||
| EOX (Epirubicin Oxaliplatin Capecitabine) | 3 (6.38%) | ||
| Ovarian Cancer | 31 | Liposomal Doxorubicin Carboplatin | 1 (3.23%) |
| Paclitaxel and Carboplatin | 30 (96.77%) | ||
| Head and Neck | 17 | Carboplatin and 5Fu (fluorouracil) | 1 (5.88%) |
| Cisplatin | 8 (47.06%) | ||
| Cisplatin and 5Fu (fluorouracil) | 1 (5.88%) | ||
| Cisplatin and Nimotozumab | 1 (5.88%) | ||
| Paclitaxel and Carboplatin | 3 (17.65%) | ||
| Pemetrexed and Carboplatin | 1 (5.88%) | ||
| TPF Chemo (Taxotere Cisplatin Fluorouracil) | 2 (11.76%) | ||
| Soft tissue Sarcoma | 17 | Ifostomide and Doxorubicin | 17 (100%) |
| Lung cancer | 14 | Cisplatin and Pemetrexed | 1 (7.14%) |
| Carboplatin | 1 (7.14%) | ||
| Cisplatin and Docetaxel | 1 (7.14%) | ||
| Cisplatin and Etoposide | 1 (7.14%) | ||
| High-dose Cisplatin | 1 (7.14%) | ||
| Paclitaxel and Carboplatin | 2 (14.29%) | ||
| Paclitaxel, Carboplatin, and Bevacizumab | 2 (14.29%) | ||
| Pemetrexed and Carboplatin | 4 (28.57%) | ||
| Pemetrexed, Carboplatin, and Zoledronic Acid | 1 (7.14%) | ||
| Pemetrexed, Carboplatin, and Bevacizumab | 1 (7.14%) | ||
| Cervix | 6 | Paclitaxel and Carboplatin | 2 (33.33%) |
| Carboplatin-150 | 1 (16.67%) | ||
| Osteosarcoma | 2 | Cisplatin and Doxorubicin | 2 (100%) |
| Pancreatic cancer | 2 | Gemcitabine and tab Capecitabine | 1 (50%) |
| Gemcitabine | 1 (50%) | ||
| Prostate cancer | 2 | Gemcitabine and Cisplatin | 1 (50%) |
| Docetaxel, Zoledronic Acid, and Prednisolone | 1 (50%) | ||
| Biliary tract cancer | 1 | Gemcitabine and Cisplatin | 1 (100%) |
| Endometrium | 1 | Paclitaxel and Carboplatin | 1 (100%) |
| Urinary bladder | 1 | Gemcitabine and Cisplatin | 1 (100%) |
| Colorectal cancer | 3 | FOLFOX Q2W (fluorouracil, leucovorin, and oxaliplatin) | 1 (33.33%) |
| FOLFIRI (Folinic acid [leucovorin] Fluorouracil [5-FU] Irinotecan) | 1 (33.33%) | ||
| Bevacizumab & FOLFOX (fluorouracil, leucovorin, and oxaliplatin) | 1 (33.33%) | ||
| Cutaneous SCC | 1 | Cisplatin | 1 (100%) |
| Dysgerminoma | 1 | BEP (bleomycin, etoposide, and cisplatin) | 1 (100%) |
| Neuro Endocrine Tumor | 1 | Epirubicin and Cyclophosphamide | 1 (100%) |
| Oligodendroglioma | 1 | Bevacizumab and Irinotecan | 1 (100%) |
| Unknown | 1 | Cisplatin | 1 (100%) |